Business
Aytu BioScience Announces Addition of Natesto(R) to Leading National Pharmacy Benefit Manager’s Formulary; Natesto Added to Commercial Plans Covering Over 30 Million U.S. Lives
During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"During the 12-month period ending June 2019, the U.S. prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenueENGLEWOOD, CO / ACCESSWIRE / September 24, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that Natesto® (testosterone nasal gel) is now on formulary and covered nationwide by a large, leading national pharmacy benefit manager (PBM). This PBM contract provides for unrestricted patient access to Natesto, the only FDA-approved nasally-administered testosterone therapy (TRT), across the PBM's commercial formularies.Over thirty million U.S. lives are covered by these prescription plans nationwide. These 30 million lives are in addition to the previously announced 6 million lives covered under a separate payer contract.During the 12-month period ending June 2019, the US prescription TRT market registered 6.9 million prescriptions, generating approximately $1.7 billion in revenue.Josh Disbrow, Chief Executive Officer of Aytu BioScience stated, \"The addition of Natesto to this leading national PBM's formulary is a meaningful step in further building Natesto into a leading brand in the United States. With the signing of this second payer contract this year, over 36 million patients have gained access to Natesto in just the past three months. We believe this expanded coverage will increase physician prescribing of Natesto and enable improved access to the more than 13 million U.S. men diagnosed with hypogonadism.\"Natesto is the only FDA-approved topically-applied therapy for low testosterone that does not have a black box warning related to transference of testosterone to children or women.About Aytu BioScience, Inc.Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or \"Low T\"). Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, the only FDA-approved oral spray prescription sleep aid. ZolpiMist is indicated for the short-term treatment of insomnia characterized by difficulties with sle...